Lilly Maps Out China Strategy
This article was originally published in PharmAsia News
Last year, even as the worldwide pharmaceutical market growth slowed down to 3.8 percent, China powered ahead with a 15 percent increase. Eli Lilly's Chairman and CEO, Sidney Taurel, revealed that the company's business in China grew by 28 percent, which greatly fueled the overall corporate global performance. China Lilly is shifting its strategy from a FIPCO (Fully Integrated Pharmaceutical Company) model to FIPNET (Fully Integrated Pharmaceutical Network) model, which emphasizes collaboration rather than acquisition. The MNC has pumped investment into its China office as well as three local enterprises in Shanghai. Lilly China is exploring opportunities in community hospitals and will participate in drug tenders called by such organizations. (Click here for more - Chinese Language)
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?